Expression patterns of ER, HER2, and NM23-H1 in breast cancer patients with different menopausal status: Correlations with metastasis

Molecular Diagnosis and Therapy

Volumn 15, Issue 4, 2011, Pages 211-219

  Dong, Su Wei ^a   Wang, Lin ^b   Sui, Jun ^a   Deng, Xi Yun ^c   Chen, Xiao Dan ^a   Zhang, Zhi Wei ^a   Liu, Xu ^d   Liu, Zhi Min ^a   Zhang, Jian Hua ^a   Yang, Qi Sheng ^a   Jia, Yong Feng ^e   Song, Xin ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d Kunming College of Medicine   (China)

^e AFFILIATED HOSPITAL OF INNER MONGOLIA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NUCLEOSIDE DIPHOSPHATE KINASE A;

ADULT; AGED; ARTICLE; BREAST CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; METASTASIS POTENTIAL; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; MENOPAUSE; MIDDLE AGED; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 80052747865     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.2165/11590360-000000000-00000     Document Type: Article

References (71)

1. Breasted JH. The Edwin Smith surgical papyrus. Chicago (IL): University of Chicago Press, 1990: 403-6
2. Ferlay J, Bray F, Pisani P, et al.GLOBOCAN2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No 5, version 2.0. Lyon: IARC Press, 2004
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58 (2): 71-96 (Pubitemid 351521864)
4. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55 (2): 74-108 (Pubitemid 40372904)
5. Hu YH, Chisato N, Hiroyuki S, et al. Association of body mass index, physical activity, and reproductive histories with breast cancer: a case-control study in Gifu, Japan. Breast Cancer Res Treat 1997; 43: 65-72
6. Tung HT, Tsukuma H, Tanaka H, et al. Risk factors for breast cancer in Japan, with special attention to anthropometric measurements and reproductive history. Jpn J Clin Oncol 1999; 29: 137-46
7. Hilakivi-Clarke L, Cabanes A, Olivo S, et al. Do estrogens always increase breast cancer risk? J Steroid Biochem Mol Biol 2002; 80: 163-74 (Pubitemid 34233738)
8. Lin KH, Wang WJ, Wu YH, et al. Activation of antimetastatic Nm23-H1 gene expression by estrogen and its alpha-receptor.Endocrinology 2002; 143 (2): 467-75
9. Read LD, Keith Jr D, Slamon DJ, et al. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 1990; 50 (13): 3947-51 (Pubitemid 20225611)
10. Ménard S, Fortis S, Castiglioni F, et al. HER2 as a prognostic factor in breast cancer. Oncology 2001; 61 Suppl. 2: 67-72 (Pubitemid 33033427)
11. Tovey S, Dunne B, Witton CJ, et al. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 2005; 11: 4835-42 (Pubitemid 41557203)
12. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000; 19: 6102-14 (Pubitemid 32059460)
13. Sugarbaker EV. Patterns of metastasis in human malignancies. Cancer Biol Rev 1981; 2: 235-78
14. Steeg PS, Bevilacqua G, Kopper L, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988; 80 (3): 200-4
15. Rosengard AM, Krutzsch HC, Shearn A, et al. Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development. Nature 1989; 342 (6246): 177-80
16. Stahl JA, Leone A, Rosengard AM, et al. Identification of a second human nm23 gene, nm23-H2. Cancer Res 1991; 51 (1): 445-9
17. Venturelli D, Martinez R, Melotti P, et al. Overexpression of DR-nm23, a protein encoded by a member of the nm23 gene family, inhibits granulocyte differentiation and induces apoptosis in 32Dc13myeloid cells. Proc Natl Acad Sci U S A 1995; 92 (16): 7435-9
18. Milon L, Rousseau-Merck MF, Munier A, et al. nm23-H4, a new member of the family of human nm23/nucleoside diphosphate kinase genes localised on chromosome 16p13. Hum Genet 1997; 99 (4): 550-7 (Pubitemid 27152109)
19. Munier A, Feral C, Milon L, et al. A new human nm23 homologue (nm23-H5) specifically expressed in testis germinal cells. FEBS Lett 1998; 434 (3): 289-94 (Pubitemid 29052242)
20. Mehus JG, Deloukas P, Lambeth DO. NME6: a new member of the nm23/nucleoside diphosphate kinase gene family located on human chromosome 3p21.3. Hum Genet 1999; 104 (6): 454-9 (Pubitemid 29370919)
21. Tsuiki H, Nitta M, Furuya A, et al. A novel human nucleoside diphosphate (NDP) kinase, Nm23-H6, localizes in mitochondria and affects cytokinesis. J Cell Biochem 1999; 76 (2): 254-69 (Pubitemid 30030773)
22. Van Golen KL, Risin S, Staroselsky A, et al. Predominance of the metastatic phenotype in hybrids formed by fusion of mouse and human melanoma clones. Clin Exp Metastasis 1996; 14 (2): 95-106 (Pubitemid 26074273)
23. Padma P, Hozumi A, Ogawa K, et al. Molecular cloning and characterization of a thioredoxin/nucleoside diphosphate kinase related dynein intermediate chain from the ascidian, Ciona intestinalis. Gene 2001; 275 (1): 177-83 (Pubitemid 32907341)
24. Freije JM,MacDonald NJ, Steeg PS. Nm23 and tumour metastasis: basic and translational advances. Biochem Soc Symp 1998; 63: 261-71 (Pubitemid 128669569)
25. Orgéas CC, Hall P, Rosenberg LU, et al. The influence of menstrual risk factors on tumor characteristics and survival in postmenopausal breast cancer. Breast Cancer Res 2008; 10 (6): R107
26. American Joint Committee on Cancer. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag 2003 [online]. Available from URL: http:// www.cancerstaging.org/products/pasteditions.html [Accessed 2011 Jul 12].
27. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101 (10): 736-50
28. Guarneri V, Giovannelli S, Ficarra G, et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008; 13 (8): 838-44
29. Rhee J, Han SW, Oh DY, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 2008; 8: 307
30. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-45 (Pubitemid 350003059)
31. Belev B, Alerić I, Vrbanec D, et al. Nm23 gene product expression in invasive breast cancer: immunohistochemical analysis and clinicopathological correlation. Acta Oncol 2002; 41 (4): 355-61
32. Gruber CJ, Tschugguel W, Schneeberger C, et al. Production and actions of estrogens. N Engl J Med 2002; 346 (5): 340-52
33. Dickson RB, Huff KK, Spencer EM, et al. Induction of epidermal growth factor-related polypeptides by 17 beta-estradiol in MCF-7 human breast cancer cells. Endocrinology 1986; 118 (1): 138-42 (Pubitemid 16186425)
34. Wilding G, Lippman ME, Gelmann EP. Effects of steroid hormones and peptide growth factors on protooncogene c-fos expression in human breast cancer cells. Cancer Res 1988; 48 (4): 802-5 (Pubitemid 18061866)
35. Dickson RB, McManaway ME, Lippman ME. Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science 1986; 232 (4757): 1540-3 (Pubitemid 16061561)
36. Dubik D, Dembinski TC, Shiu RP. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res 1987; 47 (24 Pt 1): 6517-21 (Pubitemid 18019647)
37. Sapino A, Pietribiasi F, Bussolati G, et al. Estrogen- and tamoxifen-induced rearrangement of cytoskeletal and adhesion structures in breast cancer MCF-7 cells. Cancer Res 1986; 46 (5): 2526-31 (Pubitemid 16120725)
38. Huff KK, Lippman ME. Hormonal control of plasminogen activator secretion in ZR-75-1 human breast cancer cells in culture. Endocrinology 1984; 114 (5): 1702-10 (Pubitemid 14140323)
39. Albini A, Graf J, Kitten GT, et al. 17-b-Estradiol regulates and v-Ha-ras transfection constitutively enhances MCF7 breast cancer cell interactions with basement membrane. Proc Natl Acad Sci U S A 1986; 83 (21): 8182-6 (Pubitemid 17182465)
40. Capony F, Morisset M, Barrett AJ, et al. Phosphorylation, glycosylation and proteolytic activity of the 52-kD estrogen induced protein secreted by MCF-7 cells. J Cell Biol 1987; 104 (2): 253-62
41. Laudadio J, Quigley DI, Tubbs R, et al. HER2 testing: a review of detection methodologies and their clinical performance. Expert Rev Mol Diagn 2007; 7 (1): 53-64 (Pubitemid 46114707)
42. Frogne T, Laenkholm AV, Lyng MB, et al. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor positive tumors. Breast Cancer Res 2009; 11 (1): R11
43. Berno V, Amazit L, Hinojos C, et al. Activation of estrogen receptor-alpha by E2 or EGF induces temporally distinct patterns of large-scale chromatin modification and mRNA transcription. PLoS One 2008; 3 (5): e2286
44. Baird DT, Horton R, Longcope C, et al. Steroid dynamics under steady-state conditions. Recent Prog Horm Res 1969; 25: 611-64
45. Barrett-Lee PJ, Travers MT, McClelland RA, et al. Characterization of estrogen receptor messenger RNA in human breast cancer. Cancer Res 1987; 47: 6653-9 (Pubitemid 18019671)
46. Benz CC. Impact of aging on the biology of breast cancer. Crit Rev Oncol Hematol 2008; 66 (1): 65-74 (Pubitemid 351324129)
47. de la Rosa A, Williams RL, Steeg PS. Nm23/nucleoside diphosphate kinase: toward a structural and biochemical understanding of its biological functions. Bioessays 1995; 17 (1): 53-62
48. Nakayama T, Ohtsuru A, Nakao K, et al. Expression in human hepatocellular carcinoma of nucleoside diphosphate kinase, a homologue of the nm23 gene product. J Natl Cancer Inst 1992; 84 (17): 1349-54
49. Yamaguchi A, Urano T, Goi T, et al. Expression of human nm23-H1 and nm23-H2 proteins in hepatocellular carcinoma. Cancer 1994; 73 (9): 2280-4 (Pubitemid 24129109)
50. Iizuka N, Oka M, Noma T, et al. NM23-H1 and NM23-H2 messenger RNA abundance in human hepatocellular carcinoma.CancerRes 1995; 55 (3): 652-7
51. Royds JA, Stephenson TJ, Rees RC, et al. Nm23 protein expression in ductal in situ and invasive human breast carcinoma. J Natl Cancer Inst 1993; 85 (9): 727-31 (Pubitemid 23133594)
52. Kodera Y, Isobe K, Yamauchi M, et al. Expression of nm23-H1 RNA levels in human gastric cancer tissues: a negative correlation with nodal metastasis. Cancer 1994; 73 (2): 259-65 (Pubitemid 24030599)
53. Mandai M, Konishi I, Koshiyama M, et al. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression. Cancer Res 1994; 54 (7): 1825-30 (Pubitemid 24116194)
54. Viel A, DallAgnese L, Canzonieri V, et al. Suppressive role of the metastasisrelated nm23-H1 gene in human ovarian carcinomas: association of high messenger RNA expression with lack of lymph node metastasis. Cancer Res 1995; 55 (12): 2645-50
55. Scambia G, Ferrandina G, Marone M, et al. nm23 in ovarian cancer: correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters. J Clin Oncol 1996; 14 (2): 334-42 (Pubitemid 26053263)
56. Ozeki Y, Takishima K, Mamiya G. Immunohistochemical analysis of nm23/NDP kinase expression in human lung adenocarcinoma: association with tumor progression in Clara cell type. Jpn J Cancer Res 1994; 85 (8): 840-6 (Pubitemid 24262306)
57. Zafon C, Obiols G, Castellv́ J, et al. nm23-H1 immunoreactivity as a prognostic factor in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86 (8): 3975-80 (Pubitemid 32756007)
58. Sirotkovic-Skerlev M, Krizanac S, Kapitanovic S, et al. Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters. Exp Mol Pathol 2005; 79 (1): 42-50 (Pubitemid 40984751)
59. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95 (7): 927-37 (Pubitemid 29019045)
60. Driscoll MD, Sathya G, Muyan M, et al. Sequence requirements for estrogen receptor binding to estrogen response elements. J Biol Chem 1998; 273 (45): 29321-30 (Pubitemid 28509931)
61. Kato S, Tora L, Yamauchi J, et al.Afar upstream estrogen response element of the ovalbumin gene contains several half-palindromic 50-TGACC-30 motifs acting synergistically. Cell 1992; 68 (4): 731-42
62. Näär AM, Boutin JM, Lipkin SM, et al. The orientation and spacing of core DNA-binding motifs dictate selective transcriptional responses to three nuclear receptors. Cell 1991; 65(7): 1267-79.
63. Curtis CD, Likhite VS, McLeod IX, et al. Interaction of the tumor metastasis suppressor nonmetastatic protein 23 homologue H1 and estrogen receptor A alters estrogen-responsive gene expression. Cancer Res 2007; 67 (21): 10600-7 (Pubitemid 350070837)
64. Ouatas T, Salerno M, Palmieri D, et al. Basic and translational advances in cancer metastasis: Nm23. J Bioenerg Biomembr 2003; 35: 73-9 (Pubitemid 36667583)
65. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17: 976-83 (Pubitemid 29109331)
66. Beenken SW, Grizzle WE, Crowe DR, et al. Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53. Ann Surg 2001; 233 (5): 630-8 (Pubitemid 32378646)
67. Tsutsui S, Ohno S, Murakami S, et al. Prognostic significance of the coexpression of p53 protein and c-erbB2 in breast cancer. Am J Surg 2003; 185: 165-7 (Pubitemid 36143908)
68. Patani N, Mokbel K. Herceptin and breast cancer: an overview for surgeons. Surg Oncol 2010; 19 (1): e11-21
69. Steeg PS, Horak CE, Miller KD. Clinical-translational approaches to the Nm23-H1 metastasis suppressor. Clin Cancer Res 2008; 14 (16): 5006-12
70. Marshall JC, Lee JH, Steeg PS. Clinical-translational strategies for the elevation ofNm23-H1metastasis suppressor gene expression. Mol Cell Biochem 2009; 329 (1-2): 115-20
71. Steeg PS, Ouatas T, Halverson D, et al. Metastasis suppressor genes: basic biology and potential clinical use. Clin Breast Cancer 2003; 4: 51-62 (Pubitemid 36621624)